Drugs / Micro Fragmented Adipose Tissue
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06505135 | Sep 2024 → Nov 2026 expected | rotator cuff syndrome | University of Southern Denmark | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04929951 | Jul 2022 → Dec 2027 expected | osteoarthritis | Stanford University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05005000 | May 2022 → May 2023 | arthritic joint disease | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT04230902 | Mar 2019 → Mar 2021 | osteoarthritis, knee | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03467919 | Apr 2018 → Oct 2024 | osteoarthritis, knee | Stanford University | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | micro-fragmented adipose tissue | “autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal” NCT06505135 ↗ |
| Known as | MFAT | “Micro-Fragmented Adipose Tissue (MFAT)” NCT05005000 ↗1“MFAT(Micro Fragmented Adipose Tissue)” NCT03467919 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stem cells (aMAT)” NCT04230902 ↗ |
| Route | Other | “intra-articular injection” NCT03467919 ↗ |